Union Therapeutics recruits first psoriasis patient for phase IIb study

Biotech company Union Therapeutics is now testing its psoriasis treatment orismilast in an orally administered version. It is also testing the drug in a rare indication called hidradenitis suppurativa and atopic eczema.
Photo: Union Therapeutics / PR
Photo: Union Therapeutics / PR
by ulrich quistgaard, translated by catherine brett

Union Therapeutics is attempting to find the perfect dosage of drug candidate orismilast in a phase IIb study of psoriasis patients.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading